India's Lupin settles US patent dispute with Astellas Pharma for $90 million (updated)
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Brief: Lupin Enters Settlement And License Agreement With Astellas
Table: Astellas -9-MTH group results (IFRS)
Brief: Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Merck up after FDA approves combination treatment for muscle invasive bladder cancer
Table: Astellas 6-MTH group results (IFRS)
Brief: Pfizer Co & Astellas Announce Final Overall Survival Results From Phase 3 Embark Study For Xtandi In Combination With Leuprolide
Brief: Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Brief: Astellas Pharma Inc - Astellas Confirms Phase 2 Gleam Trial Did Not Meet Primary Endpoint Of Overall Survival In Patients With Metastatic Pancreatic Cance
Brief: Vyloy (Zolbetuximab) Now Funded In Ontario And Quebec For Advanced Gastric Cancer
Brief: Pfizer Says Padcev Plus Keytruda Improves Survival for Certain Bladder Cancer Patients Pre/Post-Surgery
Pfizer's combination therapy improves survival in bladder cancer trial
Table: Astellas -Q1 group results (IFRS)
Japan national sentenced to 3-1/2 years in prison in China has no plan to appeal, Kyodo says (updated)
Japan national sentenced to 3-1/2 years in prison in China has no plan to appeal, Kyodo says
Factbox: Foreign firms' executives entangled in Chinese probes
Factbox: Foreign firms' executives entangled in Chinese probes